89 related articles for article (PubMed ID: 8139785)
1. [Therapy of simple endometrial hyperplasia with GnRH analogs. Evaluation of a multicentric ambulatory study. Preliminary results].
Zagni R; Cortelazzi R; Cipolla L; Giannetta G; Ferrante B; Soliani A
Minerva Ginecol; 1993 Dec; 45(12):597-602. PubMed ID: 8139785
[TBL] [Abstract][Full Text] [Related]
2. [THe use of leuprolide in endometrial glandular hyperplasia].
Menozzi G; Gozzi M; Greci P; Straticò G; Talarico G
Minerva Ginecol; 1992; 44(7-8):383-6. PubMed ID: 1407643
[TBL] [Abstract][Full Text] [Related]
3. [Use of a GnRH analogue in the treatment of certain forms of endometrial hyperplasia associated with menometrorrhagia].
Bonfirraro G; Sanna B; De Marco A; Chieffi O; Bonfirraro PP; Orlando V
Minerva Ginecol; 1995 Oct; 47(10):467-70. PubMed ID: 8559438
[TBL] [Abstract][Full Text] [Related]
4. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study.
Grimbizis G; Tsalikis T; Tzioufa V; Kasapis M; Mantalenakis S
Hum Reprod; 1999 Feb; 14(2):479-84. PubMed ID: 10099998
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of hyperplasia endometrium with GNRH agonists].
Radowicki S; Skórzewska K
Ginekol Pol; 2003 Sep; 74(9):836-9. PubMed ID: 14674133
[TBL] [Abstract][Full Text] [Related]
6. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data.
Agorastos T; Bontis J; Vakiani A; Vavilis D; Constantinidis T
Gynecol Oncol; 1997 Apr; 65(1):102-14. PubMed ID: 9103399
[TBL] [Abstract][Full Text] [Related]
7. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
Zhao LJ; Wei LH; Li XP; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and therapy of low-risk endometrial hyperplasia. Experience with LH-RH-A].
Pace S; Stentella P; Frega A; Palazzetti PL; Nobili F; Figliolini M; Grassi A
Minerva Ginecol; 1992 Dec; 44(12):645-51. PubMed ID: 1491773
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.
Zhang Z; Huang H; Feng F; Wang J; Cheng N
J Gynecol Oncol; 2019 Jul; 30(4):e61. PubMed ID: 31074242
[TBL] [Abstract][Full Text] [Related]
10. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up.
Pérez-Medina T; Bajo J; Folgueira G; Haya J; Ortega P
Gynecol Oncol; 1999 May; 73(2):299-304. PubMed ID: 10329050
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
12. The dynamics of endometrial growth and the triple layer appearance in three different controlled ovarian hyperstimulation protocols and their influence on IVF outcomes.
Kuć P; Kuczyńska A; Topczewska M; Tadejko P; Kuczyński W
Gynecol Endocrinol; 2011 Nov; 27(11):867-73. PubMed ID: 21231852
[TBL] [Abstract][Full Text] [Related]
13. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
[TBL] [Abstract][Full Text] [Related]
14. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
Zenaty D; Blumberg J; Liyanage N; Jacqz-Aigrain E; Lahlou N; Carel JC;
Horm Res Paediatr; 2016; 86(3):188-195. PubMed ID: 27603324
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.
Filicori M; Flamigni C; Cognigni G; Dellai P; Arnone R; Falbo A; Capelli M
J Clin Endocrinol Metab; 1993 Jul; 77(1):130-3. PubMed ID: 8325935
[TBL] [Abstract][Full Text] [Related]
16. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
Shore ND; Sieber P; Schimke L; Perzin A; Olsen S
Urol Nurs; 2013; 33(5):236-44, 248. PubMed ID: 24354113
[TBL] [Abstract][Full Text] [Related]
18. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study.
Pashov AI; Tskhay VB; Ionouchene SV
Gynecol Endocrinol; 2012 Jul; 28(7):559-61. PubMed ID: 22296608
[TBL] [Abstract][Full Text] [Related]
19. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S
Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411
[TBL] [Abstract][Full Text] [Related]
20. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
